Global Bioresorbable Coronary Stents Market Size By Type (Absorb BVS, Absorb 2nd Generation), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Bioresorbable Coronary Stents Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 3.2 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2023–2031). Bioresorbable stents are designed to provide temporary scaffolding to the artery after percutaneous coronary intervention (PCI) and are gradually absorbed by the body, eliminating long-term risks associated with permanent metal stents. The market is experiencing substantial growth due to the increasing prevalence of coronary artery disease (CAD), rising demand for next-generation stent technologies, and the shift toward minimally invasive procedures.

Drivers:

1. Growing Prevalence of Cardiovascular Diseases (CVDs):

The global rise in CVDs, particularly coronary artery disease, is driving the demand for effective treatment solutions such as bioresorbable coronary stents. These stents reduce the risk of long-term complications associated with metal implants and are gaining preference in clinical practice.

2. Increasing Preference for Minimally Invasive Procedures:

Surgeons and patients alike are gravitating toward less invasive treatments, which result in quicker recovery times and lower healthcare costs. Bioresorbable stents support this trend due to their temporary nature and minimal long-term interference with vascular physiology.

3. Technological Innovations:

Ongoing R&D is leading to the development of thinner, stronger, and more biocompatible materials for bioresorbable stents. Innovations such as drug-eluting designs and polymer engineering are enhancing stent performance, encouraging broader adoption.

Restraints:

1. High Cost and Reimbursement Challenges:

Bioresorbable stents are significantly more expensive than conventional metallic stents, which may limit their accessibility, especially in cost-sensitive regions. Inadequate insurance coverage further hampers market penetration.

2. Clinical Limitations and Regulatory Hurdles:

Concerns over long-term efficacy, as well as past clinical trial setbacks, have raised caution among cardiologists. Additionally, gaining regulatory approval for new bioresorbable technologies remains a lengthy and complex process.

Opportunity:

1. Expansion in Emerging Markets:

Rising healthcare expenditures and growing awareness of advanced medical devices in Asia-Pacific, Latin America, and the Middle East offer vast opportunities for market players to introduce affordable and effective bioresorbable stents.

2. Strategic Collaborations:

Collaborations between medical device companies, research institutions, and healthcare providers are likely to accelerate innovation and market access for bioresorbable coronary stents globally.

Market by System Type Insights:

The polymeric bioresorbable stents segment held the largest market share in 2023 due to their biocompatibility and extensive clinical research backing. However, metal-based bioresorbable stents (such as magnesium-based stents) are expected to grow at the fastest pace due to improved mechanical strength and resorption rates.

Market by End-Use Insights:

Hospitals and cardiac centers dominated the market in 2023, accounting for over 60% of revenue share. This is attributed to high volumes of PCI procedures, advanced infrastructure, and skilled professionals. Ambulatory surgical centers (ASCs) are anticipated to experience faster growth due to the shift toward outpatient care and cost-effective treatment settings.

Market by Regional Insights:

North America led the global market in 2023, driven by a high burden of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of innovative stenting technologies. Meanwhile, the Asia-Pacific region is expected to register the fastest CAGR during the forecast period, fueled by expanding healthcare access, increasing CAD incidence, and rising medical tourism.

Competitive Scenario:

Key players in the Global Bioresorbable Coronary Stents Market include Abbott Laboratories, Biotronik, Elixir Medical Corporation, Boston Scientific Corporation, Arterius Ltd., and REVA Medical. These companies are investing heavily in clinical trials, regulatory clearances, and global distribution networks to enhance their market position.

Scope of Work – Global Bioresorbable Coronary Stents Market

Key Market Developments:

2023: Abbott Laboratories initiated a multi-center clinical trial for its next-gen magnesium-based bioresorbable stent platform, aiming to address prior performance limitations.

2024: Boston Scientific acquired a startup specializing in biodegradable stent coatings to expand its portfolio in the interventional cardiology space.

2025: Elixir Medical announced positive outcomes from a large-scale registry study supporting the long-term safety of its DESolve bioresorbable scaffold in complex lesions.

FAQs:

1. What is the current market size of the Global Bioresorbable Coronary Stents Market?

The market was valued at USD 1.3 billion in 2023.

2. What is the major growth driver of the Global Bioresorbable Coronary Stents Market?

The key driver is the rising prevalence of coronary artery disease and the shift toward minimally invasive, resorbable treatment solutions.

3. Which is the largest region during the forecast period in the Global Bioresorbable Coronary Stents Market?

North America holds the largest share, while Asia-Pacific is the fastest-growing region.

4. Which segment accounted for the largest market share in the Global Bioresorbable Coronary Stents Market?

The polymeric stents segment held the largest market share in 2023.

5. Who are the key market players in the Global Bioresorbable Coronary Stents Market?

Key players include Abbott Laboratories, Biotronik, Elixir Medical, Boston Scientific, Arterius, and REVA Medical.